Mapping the Global Landscape for Induced Pluripotent Stem Cells from Patents and Clinical Trials

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2024 Apr 17

PMID 38632441

Authors

Liyang Lyu

Ye Feng

Borong Huang

Ren-He Xu

Yuanjia Hu

Affiliations

Soon will be listed here.

Citing Articles

Development and evaluation of siRNA-mediated gene silencing strategies for ADO2 therapy utilizing iPSCs model and DMPC-SPIONs delivery system.

Xu J, Chen G, Mo C, Sha Y, Luo S, Ou M Stem Cell Res Ther. 2025; 16(1):66.

PMID: 39934917 PMC: 11816505. DOI: 10.1186/s13287-025-04151-6.

Global Knowledge Map and Emerging Research Trends in Induced Pluripotent Stem Cells and Hereditary Diseases: A CiteSpace-based Visualization and Analysis.

Xu J, Gong W, Mo C, Hou X, Ou M Stem Cell Rev Rep. 2024; 21(1):126-146.

PMID: 39377988 DOI: 10.1007/s12015-024-10799-z.

References

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

Thomson J, Itskovitz-Eldor J, Shapiro S, Waknitz M, Swiergiel J, Marshall V . Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282(5391):1145-7. DOI: 10.1126/science.282.5391.1145. View

Yu J, Vodyanik M, Smuga-Otto K, Antosiewicz-Bourget J, Frane J, Tian S . Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318(5858):1917-20. DOI: 10.1126/science.1151526. View

Yamanaka S . Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges. Cell Stem Cell. 2020; 27(4):523-531. DOI: 10.1016/j.stem.2020.09.014. View

Kamao H, Mandai M, Okamoto S, Sakai N, Suga A, Sugita S . Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Reports. 2014; 2(2):205-18. PMC: 3923225. DOI: 10.1016/j.stemcr.2013.12.007. View

Kleiman R, Engle S . Human inducible pluripotent stem cells: Realization of initial promise in drug discovery. Cell Stem Cell. 2021; 28(9):1507-1515. DOI: 10.1016/j.stem.2021.08.002. View

Patel M, Yang S . Advances in reprogramming somatic cells to induced pluripotent stem cells. Stem Cell Rev Rep. 2010; 6(3):367-80. PMC: 2924949. DOI: 10.1007/s12015-010-9123-8. View

Takahashi K, Yamanaka S . A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol. 2016; 17(3):183-93. DOI: 10.1038/nrm.2016.8. View

Warren L, Manos P, Ahfeldt T, Loh Y, Li H, Lau F . Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010; 7(5):618-30. PMC: 3656821. DOI: 10.1016/j.stem.2010.08.012. View

10.

Miyazaki T, Futaki S, Suemori H, Taniguchi Y, Yamada M, Kawasaki M . Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. Nat Commun. 2012; 3:1236. PMC: 3535336. DOI: 10.1038/ncomms2231. View

11.

Tiscornia G, Vivas E, Izpisua Belmonte J . Diseases in a dish: modeling human genetic disorders using induced pluripotent cells. Nat Med. 2011; 17(12):1570-6. DOI: 10.1038/nm.2504. View

12.

McCauley H, Wells J . Pluripotent stem cell-derived organoids: using principles of developmental biology to grow human tissues in a dish. Development. 2017; 144(6):958-962. PMC: 5358106. DOI: 10.1242/dev.140731. View

13.

Lee G, Papapetrou E, Kim H, Chambers S, Tomishima M, Fasano C . Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 2009; 461(7262):402-6. PMC: 2784695. DOI: 10.1038/nature08320. View

14.

Song B, Cha Y, Ko S, Jeon J, Lee N, Seo H . Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. J Clin Invest. 2019; 130(2):904-920. PMC: 6994130. DOI: 10.1172/JCI130767. View

15.

Li M, Zhong A, Wu Y, Sidharta M, Beaury M, Zhao X . Transient inhibition of p53 enhances prime editing and cytosine base-editing efficiencies in human pluripotent stem cells. Nat Commun. 2022; 13(1):6354. PMC: 9613702. DOI: 10.1038/s41467-022-34045-7. View

16.

Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T . Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. N Engl J Med. 2017; 376(11):1038-1046. DOI: 10.1056/NEJMoa1608368. View

17.

da Cruz L, Fynes K, Georgiadis O, Kerby J, Luo Y, Ahmado A . Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol. 2018; 36(4):328-337. DOI: 10.1038/nbt.4114. View

18.

Lund R, Narva E, Lahesmaa R . Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet. 2012; 13(10):732-44. DOI: 10.1038/nrg3271. View

19.

Bravery C . Do human leukocyte antigen-typed cellular therapeutics based on induced pluripotent stem cells make commercial sense?. Stem Cells Dev. 2014; 24(1):1-10. DOI: 10.1089/scd.2014.0136. View

20.

Ben Jehuda R, Shemer Y, Binah O . Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9. Stem Cell Rev Rep. 2018; 14(3):323-336. DOI: 10.1007/s12015-018-9811-3. View